Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:54:55 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:TEVA from 2023-05-07 to 2024-05-06 - 53 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 18:30U:TEVANews ReleaseTeva to Present at the 2024 Bank of America Healthcare Conference
2024-05-02 08:30U:TEVANews ReleaseTeva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
2024-04-30 04:00U:TEVANews ReleaseU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira(TM) (adalimumab)
2024-04-30 04:00U:TEVANews ReleaseU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira(TM) (adalimumab)
2024-04-16 17:43U:TEVANews ReleaseAlvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(TM) (ustekinumab)
2024-04-16 17:30U:TEVANews ReleaseAlvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(TM) (ustekinumab)
2024-04-16 08:00U:TEVANews ReleaseTeva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO(TM) (deutetrabenazine) Tablets
2024-04-11 08:30U:TEVANews ReleaseTeva Confirms Efficacy and Safety of AJOVY(TM) (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
2024-04-09 16:30U:TEVANews ReleaseTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
2024-04-06 13:00U:TEVANews ReleaseNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY(TM) (risperidone) Extended-Release Injectable Suspension at SIRS 2024
2024-04-04 08:30U:TEVANews ReleaseTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
2024-04-01 08:30U:TEVANews ReleaseClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-'248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
2024-02-26 07:00U:TEVANews ReleaseTeva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO(TM) in China
2024-02-23 20:15U:TEVANews ReleaseAlvotech and Teva Announce U.S. Approval of SIMLANDI(TM) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(TM)
2024-02-23 20:15U:TEVANews ReleaseAlvotech and Teva Announce U.S. Approval of SIMLANDI(TM) (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira(TM)
2024-02-20 08:30U:TEVANews ReleaseTeva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV- ¢ € ˜574) Antibody at the 2024 ECCO Annual Meeting
2024-01-31 07:00U:TEVANews ReleaseTeva Reports Growth in Fourth Quarter and Full Year 2023
2024-01-31 06:00U:TEVANews ReleaseTeva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
2024-01-02 16:30U:TEVANews ReleaseTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
2023-12-28 16:30U:TEVANews ReleaseTeva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 08:30U:TEVANews ReleaseTeva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
2023-12-06 02:00U:TEVANews ReleaseNew Post Hoc Phase 3 Data Analysis Shows AJOVY ‚ ® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
2023-11-30 08:30U:TEVANews ReleaseTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
2023-11-20 16:30U:TEVANews ReleaseTeva to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-17 08:30U:TEVANews ReleaseTeva Announces Approval of a Generic Version of Forteo ‚ ® (teriparatide injection), in the U.S.
2023-11-13 08:10U:TEVANews ReleaseRoyalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
2023-11-13 08:00U:TEVANews ReleaseTeva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
2023-11-08 07:00U:TEVANews ReleaseTeva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
2023-11-07 16:30U:TEVANews ReleaseTeva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
2023-11-02 08:00U:TEVANews ReleaseTeva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO ‚ ® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
2023-10-25 09:00U:TEVANews ReleaseTeva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
2023-10-17 01:30U:TEVANews ReleaseTeva Phase IV UNITE Study Shows AJOVY ‚ ® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
2023-10-04 01:07U:TEVANews ReleaseSanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
2023-09-28 16:05U:TEVANews ReleaseTeva Announces Changes to Executive Management Team
2023-09-06 08:00U:TEVANews ReleaseTeva to Present Data for AUSTEDO ‚ ® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO ‚ ® (deutetrabenazine) Tablets and UZEDY ¢ „ ¢ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
2023-08-21 16:00U:TEVANews ReleaseTeva Settles Price Fixing Charges With U.S. DOJ
2023-08-02 07:00U:TEVANews ReleaseTeva Reports Second Quarter 2023 Financial Results
2023-07-27 08:00U:TEVANews ReleaseTeva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
2023-07-24 04:00U:TEVANews ReleaseTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
2023-07-24 04:00U:TEVANews ReleaseTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
2023-07-05 16:30U:TEVANews ReleaseTeva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
2023-06-30 12:30U:TEVANews ReleaseTeva ¢ € ™s 3rd interim analysis of PEARL real-world study on AJOVY ‚ ® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
2023-06-15 08:00U:TEVANews ReleaseTeva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY ‚ ® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
2023-06-12 07:00U:TEVANews ReleaseAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ‚ ®
2023-06-12 03:00U:TEVANews ReleaseAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ‚ ®
2023-06-08 08:30U:TEVANews ReleaseTeva Concludes Nationwide Opioids Settlement Agreement
2023-06-06 08:00U:TEVANews ReleasePhil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler ‚ ® Family of Inhalers to Support Asthma Management
2023-06-02 16:30U:TEVANews ReleaseTeva Presents Real-World Data for AUSTEDO ‚ ® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
2023-05-20 11:00U:TEVANews ReleaseTeva to Present Data Demonstrating UZEDY ¢ „ ¢ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association ¢ € ™s 2023 Annual Meeting
2023-05-18 08:30U:TEVANews ReleaseTeva Launches New ¢ € œPivot to Growth ¢ €  Strategy
2023-05-15 08:00U:TEVANews ReleaseAUSTEDO ‚ ® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO ‚ ®, Now Available in the U.S.
2023-05-10 07:00U:TEVANews ReleaseTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
2023-05-09 07:00U:TEVANews ReleaseTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule